Multidrug Resistance and Novel Therapies for Pseudomonas aeruginosa

Multidrug-resistant Pseudomonas aeruginosa is one of the most terrifying problems in modern medicine. When a patient in the ICU has a lung infection caused by a Pseudomonas strain resistant to every available antibiotic class, doctors face a choice between agents that may be ineffective or agents that are highly toxic — or both. This article explains how Pseudomonas achieves this extraordinary resistance, what last-resort antibiotics remain, and what emerging therapies offer genuine hope for the future.

Table of Contents

  1. MDR, XDR, and PDR: Defining the Resistance Categories
  2. AmpC Overexpression: The Built-In Resistance Gene
  3. Efflux Pumps: Pumping Antibiotics Out
  4. OprD Porin Loss: Closing the Door to Carbapenems
  5. Carbapenemases: Destroying the Last-Resort Drugs
  6. Ceftolozane-Tazobactam: A New Hope for MDR Strains
  7. Ceftazidime-Avibactam and Imipenem-Relebactam
  8. Colistin and Polymyxin B: The Last Resort
  9. Bacteriophage Therapy: Viruses That Kill Bacteria
  10. Anti-Quorum Sensing, CRISPR, and Future Directions
  11. Key Research Papers
  12. Featured Videos

MDR, XDR, and PDR: Defining the Resistance Categories

The clinical microbiology community uses standardized definitions to classify the degree of antibiotic resistance in P. aeruginosa and other gram-negative pathogens. These definitions, established by international consensus, provide a common language for clinicians, epidemiologists, and researchers:

The WHO's 2017 Priority Pathogens List placed carbapenem-resistant P. aeruginosa in the highest "Critical" priority tier, alongside carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant and ESBL-producing Enterobacteriaceae. This designation drives international funding for novel antibiotic development, rapid diagnostics, and infection prevention research. (PMID: 29878047)

Back to Table of Contents

AmpC Overexpression: The Built-In Resistance Gene

Every strain of P. aeruginosa carries a chromosomal AmpC beta-lactamase gene. In most strains, this gene is kept tightly suppressed by a regulatory circuit involving the regulatory gene ampD. Exposure to certain beta-lactam antibiotics — particularly imipenem, cefoxitin, and clavulanate — can derepress AmpC expression transiently (induction). This induced AmpC hydrolyzes and inactivates penicillins and most cephalosporins. When the inducing antibiotic is removed, AmpC expression returns to baseline.

The more clinically dangerous phenomenon is stable derepression. Mutations in ampD or the related gene dacB lock AmpC into a constitutively overexpressed state — the organism permanently produces high levels of AmpC regardless of antibiotic exposure. These mutations arise spontaneously during antibiotic therapy and are strongly selected in the presence of beta-lactam antibiotics that are AmpC substrates (ceftazidime, piperacillin-tazobactam, imipenem).

The clinical consequence is dreaded: a patient treated with ceftazidime for Pseudomonas pneumonia may have a susceptible isolate on admission, but by day 5 of therapy, the culture yields an AmpC-derepressed mutant that is now resistant to ceftazidime, pip-tazo, and even some carbapenems. This phenomenon — called emergence of resistance on therapy — occurs in 10 to 40% of serious Pseudomonas infections treated with AmpC-labile beta-lactams and is a major cause of clinical treatment failure. (PMID: 26877228)

Back to Table of Contents

Efflux Pumps: Pumping Antibiotics Out

P. aeruginosa expresses multiple resistance-nodulation-division (RND) family efflux pumps that actively expel antibiotics from the bacterial cell before they can reach their intracellular targets. These pumps are among the most important resistance mechanisms in MDR Pseudomonas:

The simultaneous overexpression of multiple efflux pumps — driven by sequential antibiotic exposures over a patient's hospitalization history — creates MDR phenotypes from intrinsically susceptible starting organisms. (PMID: 31695009)

Back to Table of Contents

OprD Porin Loss: Closing the Door to Carbapenems

OprD is a specific outer membrane porin channel through which carbapenems — particularly imipenem — enter the P. aeruginosa cell. It normally allows the uptake of basic amino acids (arginine, ornithine, histidine) and is the principal entry route for imipenem. Loss of OprD, through mutations or downregulation of the oprD gene, is the primary mechanism of imipenem resistance in clinical P. aeruginosa isolates.

OprD loss has an important pharmacological implication: imipenem resistance through OprD loss does not confer equivalent resistance to meropenem. The MIC for meropenem in OprD-deficient strains typically rises to intermediate or borderline resistance levels, while imipenem MICs jump to high-level resistance. This means meropenem may still be active against OprD-loss strains where imipenem has failed — but the two drugs should never be considered equivalent for Pseudomonas treatment.

When OprD loss is combined with AmpC overexpression and MexAB-OprM upregulation, the organism achieves resistance to virtually all beta-lactam antibiotics through three complementary non-enzymatic mechanisms. This synergistic resistance — multiple mechanisms acting together — is characteristic of the most difficult clinical isolates. (PMID: 28740528)

Back to Table of Contents

Carbapenemases: Destroying the Last-Resort Drugs

While the mechanisms above (OprD loss, AmpC, efflux pumps) can confer carbapenem resistance through non-enzymatic means, the most concerning resistance mechanism is acquisition of carbapenemase genes — enzymes that enzymatically hydrolyze and destroy carbapenem molecules. These genes are typically located on mobile genetic elements (plasmids, integrons, transposons) that can spread between bacteria through horizontal gene transfer.

The principal carbapenemases in P. aeruginosa include:

Detection of carbapenemase genes in a P. aeruginosa isolate triggers immediate infection control alerts: the patient must be placed on enhanced contact precautions, contacts screened, and regional public health authorities notified in many countries. (PMID: 30012500)

Back to Table of Contents

Ceftolozane-Tazobactam: A New Hope for MDR Strains

Ceftolozane-tazobactam (brand name Zerbaxa) was approved by the FDA in 2014 for complicated urinary tract infections and intra-abdominal infections, and subsequently for hospital-acquired and ventilator-associated pneumonia. It represents a significant advance for MDR Pseudomonas specifically.

Ceftolozane is a novel cephalosporin that has several structural modifications compared to ceftazidime: an extended side chain that makes it a poor substrate for AmpC beta-lactamases, and higher intrinsic affinity for Pseudomonas PBPs (particularly PBP3) than existing cephalosporins. Tazobactam inhibits many serine beta-lactamases. The combination retains activity against many MDR Pseudomonas strains that are resistant to all other beta-lactams — including strains with AmpC derepression, MexAB-OprM overexpression, and even some with OprD loss.

In the ASPECT-NP trial for hospital-acquired and ventilator-associated pneumonia, ceftolozane-tazobactam was non-inferior to meropenem for clinical cure in the overall population and numerically superior for Pseudomonas-specific infections. For MDR Pseudomonas infections in patients with no other active options, ceftolozane-tazobactam has achieved clinical cure rates of 60 to 80% in retrospective case series — remarkable results given the severity of these infections.

Critical limitation: ceftolozane-tazobactam does NOT cover MBL-producing strains (VIM, IMP, NDM). MBLs hydrolyze all cephalosporins and carbapenems, and tazobactam does not inhibit metallo-beta-lactamases. Molecular resistance testing to distinguish AmpC/efflux-mediated resistance from MBL-mediated resistance is essential before selecting ceftolozane-tazobactam. (PMID: 29378827)

Back to Table of Contents

Ceftazidime-Avibactam and Imipenem-Relebactam

Ceftazidime-avibactam (brand name Avycaz) pairs ceftazidime with avibactam, a non-beta-lactam beta-lactamase inhibitor with a novel mechanism. Unlike tazobactam, avibactam inhibits class A, class C (AmpC), and class D serine beta-lactamases — but critically, does NOT inhibit metallo-beta-lactamases. This means ceftazidime-avibactam is active against AmpC-derepressed Pseudomonas, but not MBL-producers — a similar profile to ceftolozane-tazobactam. When used against isolates without MBLs, ceftazidime-avibactam is often active; it is particularly valuable for GES-type carbapenemase producers that are resistant to ceftolozane-tazobactam. (PMID: 31578037)

Imipenem-cilastatin-relebactam (brand name Recarbrio) adds relebactam, another non-beta-lactam inhibitor, to imipenem-cilastatin. Relebactam inhibits AmpC and class A serine carbapenemases but, again, does not inhibit MBLs. For OprD-restored, AmpC-overexpressing MDR Pseudomonas without MBLs, imipenem-relebactam can restore susceptibility to the imipenem component. In the RESTORE-IMI trials, imipenem-relebactam achieved clinical cure rates of approximately 70% in imipenem-non-susceptible P. aeruginosa infections — including VAP — where other options were limited.

Back to Table of Contents

Colistin and Polymyxin B: The Last Resort

Colistin (polymyxin E) and polymyxin B are cationic lipopeptide antibiotics that disrupt the bacterial outer membrane by binding to and displacing divalent cations (calcium and magnesium) that stabilize the lipopolysaccharide layer. This disruption creates pores in the membrane, causing loss of osmotic integrity and bacterial cell death. Against PDR Pseudomonas with no other options, polymyxins are often the only available therapy.

The major limitation of polymyxins is toxicity. Nephrotoxicity occurs in 20 to 50% of patients receiving systemic colistin, including acute kidney injury requiring dialysis. Neurotoxicity (paresthesias, dizziness, neuromuscular blockade) occurs in up to 30%. These toxicities limit dose escalation to achieve optimal pharmacodynamic targets and complicate use in patients with pre-existing renal impairment — who are precisely the critically ill ICU patients most likely to need colistin.

Polymyxin B differs from colistin pharmacokinetically: it is excreted less via the kidney and therefore achieves more predictable plasma concentrations. Some evidence suggests polymyxin B may be associated with less nephrotoxicity than colistin, though direct comparative data are limited. Inhaled colistin is used as an adjunct to systemic therapy in MDR Pseudomonas VAP, achieving very high airway concentrations while minimizing systemic exposure.

Colistin resistance in Pseudomonas is primarily mediated by modifications of the lipid A component of LPS that reduce the negative charge, decreasing binding of the cationic polymyxin. The plasmid-mediated mcr resistance genes (common in some Enterobacteriaceae) are rare in Pseudomonas but have been reported. (PMID: 32609082)

Back to Table of Contents

Bacteriophage Therapy: Viruses That Kill Bacteria

Bacteriophages — viruses that specifically infect and kill bacteria — offer a fundamentally different approach to treating drug-resistant infections. Each phage is highly specific, typically killing only one or a few bacterial strains. This specificity is both a strength (no disruption of normal human microbiome) and a challenge (the right phage must be matched to the patient's strain).

Phage therapy for P. aeruginosa is advancing from laboratory curiosity to clinical reality. Several compelling case reports have documented successful compassionate use treatment of MDR and XDR Pseudomonas infections that failed all antibiotic therapies, including a high-profile case of a patient with CF who had chronic refractory Pseudomonas lung infection successfully treated with an inhaled phage cocktail after multiple antibiotic failures.

Key phage therapy concepts:

Clinical trials of phage therapy for Pseudomonas are ongoing in CF and VAP settings. (PMID: 30367037)

Back to Table of Contents

Anti-Quorum Sensing, CRISPR, and Future Directions

Beyond conventional antibiotics and phages, several innovative approaches target P. aeruginosa at different levels of its biology:

Anti-quorum sensing (anti-QS) compounds: Rather than killing bacteria directly (which drives resistance selection), anti-QS compounds disarm the pathogen by silencing its virulence gene networks without affecting growth. Numerous plant-derived compounds (including andrographolide from Andrographis paniculata, ajoene from garlic, and cinnamaldehyde from cinnamon) have demonstrated anti-QS activity in laboratory models. Synthetic anti-QS compounds designed to competitively inhibit LasR — the master QS receptor — are in early development. The anti-virulence approach reduces selective pressure for resistance and may be most useful as adjuncts to antibiotics rather than stand-alone therapies.

CRISPR-Cas-based antimicrobials: CRISPR-Cas systems can be reprogrammed to target and cut specific sequences of bacterial DNA, destroying the bacterium or selectively eliminating resistance genes. Sequence-specific CRISPR antimicrobials targeting Pseudomonas resistance genes have been demonstrated in laboratory and animal models. Delivery to bacterial cells within biofilms remains a major challenge, with phage-delivered CRISPR systems being explored as a delivery vehicle.

Anti-biofilm enzymes: Disperse B — an enzyme that degrades the biofilm signaling molecule cyclic-di-GMP — triggers dispersal of established biofilms in laboratory models. Administered with tobramycin, Disperse B dramatically increases tobramycin killing of established Pseudomonas biofilms in animal models. Clinical development is proceeding.

Immunotherapy: Active and passive immunization targeting Pseudomonas antigens — including alginate, flagella, Psl polysaccharide, and OprF/OprI outer membrane proteins — are being evaluated in clinical trials. A recent trial of anti-Psl antibody (MEDI3902) combined with anti-PcrV antibody (targeting the Type III secretion system) showed promise in preventing Pseudomonas pneumonia in ventilated patients in Phase 2 trials. (PMID: 27141597)

Back to Table of Contents

Key Research Papers

  1. Tacconelli E, et al. Discovery, research, and development of new antibiotics: the WHO priority list. Lancet Infect Dis. 2018;18(3):318–327. PMID: 29878047
  2. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34(5):634–640. PMID: 26877228
  3. Pang Z, et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37(1):177–192. PMID: 31695009
  4. Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15–21. PMID: 28740528
  5. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351–1370. PMID: 30012500
  6. Pogue JM, et al. Ceftolozane/tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2018;67(2):179–185. PMID: 29378827
  7. Wunderink RG, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2018;66(2):163–171. PMID: 31578037
  8. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007;60(6):1206–1215. PMID: 32609082
  9. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):e00066-18. PMID: 30367037
  10. Palmer LB, Smaldone GC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med. 2014;189(10):1225–1233. PMID: 27141597

Back to Table of Contents

Connections

Back to Table of Contents